5,115 Shares in Revolution Medicines, Inc. $RVMD Purchased by Park Avenue Institutional Advisers LLC

Park Avenue Institutional Advisers LLC acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 5,115 shares of the company’s stock, valued at approximately $407,000. Revolution Medicines comprises about 40.5% of Park Avenue Institutional Advisers LLC’s holdings, making the stock its largest holding.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock worth $1,331,739,000 after buying an additional 1,056,792 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Revolution Medicines by 194.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company’s stock worth $1,696,000 after buying an additional 14,062 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in Revolution Medicines by 39.3% in the 3rd quarter. New York State Common Retirement Fund now owns 119,807 shares of the company’s stock worth $5,595,000 after buying an additional 33,821 shares during the last quarter. Raiffeisen Bank International AG acquired a new stake in Revolution Medicines in the 3rd quarter worth about $921,000. Finally, Mass General Brigham Inc acquired a new stake in Revolution Medicines in the 4th quarter worth about $27,407,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on RVMD shares. Oppenheimer lifted their price objective on Revolution Medicines from $165.00 to $195.00 and gave the stock an “outperform” rating in a report on Monday. Piper Sandler raised their target price on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Benchmark reissued an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. HC Wainwright raised their target price on shares of Revolution Medicines from $169.00 to $195.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Truist Financial assumed coverage on shares of Revolution Medicines in a research note on Monday, May 18th. They issued a “buy” rating and a $179.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $123.72.

Revolution Medicines Trading Down 7.6%

RVMD opened at $151.31 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The company’s 50 day simple moving average is $130.74 and its two-hundred day simple moving average is $105.50. Revolution Medicines, Inc. has a 1-year low of $34.00 and a 1-year high of $166.50. The firm has a market capitalization of $32.17 billion, a price-to-earnings ratio of -21.40 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period last year, the firm earned ($1.13) EPS. Analysts expect that Revolution Medicines, Inc. will post -7.75 EPS for the current fiscal year.

Insider Activity

In other news, insider Stephen Michael Kelsey sold 4,302 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $427,962.96. Following the sale, the insider owned 295,398 shares of the company’s stock, valued at approximately $29,386,193.04. The trade was a 1.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Xiaolin Wang sold 2,010 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider directly owned 116,063 shares in the company, valued at approximately $11,545,947.24. The trade was a 1.70% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 148,592 shares of company stock worth $20,855,132. 7.60% of the stock is owned by company insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.